NLS drug-2

Cantargia has reported data from two clinical trials including nadunolimab combination therapy in 55 cancer patients.

“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there are many existing biomarkers and faster trials,” says Medaffcon’s Scientific Advisor, PhD Riikka Mattila. According to Mattila, Medaffcon can assist pharmaceutical companies in their research […]

Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC). In short, the result showed that 86 percent overall reduction of tumor size, 51 percent complete clearance rate of basal cell carcinomas (total removal), and 71 percent average reduction in tumor size of patients with […]

Affibody’s partner ACELYRIN has announced that the Phase 3 trial of the Affibody molecule izokibep in patients with hidradenitis suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as well as the key secondary endpoints of HiSCR90 and HiSCR100. “We are delighted that the Phase 3 HS trial of izokibep was successful, again confirming […]

TikoMed has announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label, phase II clinical trial encompassing long-term weekly ILB injections for up to 48 weeks of […]

The topline data readout from the Phase II FOCUS trial demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival or overall survival in those late-stage HNSCC patients, therefore, the study did not meet its primary and secondary endpoints. “We have implemented a broad Phase […]